| Name | Title | Contact Details |
|---|
Delinea is an ISO 9001:2015 certified CNC manufacturing company which specializes in 3+2 positional and 3 axis precision milling. Founded in 2019 by Vincent and Dan Krische, Delinea is based out of a 4,800 square foot facility in Loveland Colorado. Featuring state-of-the-art equipment and automated software we provide the crucial digital manufacturing service that you need in order to become top of your industry and a leader in innovation.
Grant Thornton una de las firmas líderes a nivel mundial de servicios profesionales de Auditoría, Consultoría de Negocio, Tecnología e Innovación y Asesoramiento Fiscal, Legal, Financiero, Laboral y Outsourcing. Pertenecemos a una de las organizaciones y red líderes en servicios profesionales en todo el mundo, Grant Thornton International, con más de 73.000 profesionales presentes en más de 147 mercados. En España contamos con un equipo multidisciplinar, transversal, con experiencia y visión empresarial, que da servicio a más de 4.000 clientes en 10 oficinas repartidas por el territorio nacional: Madrid, Barcelona, Bilbao, Castellón, Las Palmas, Murcia, Valencia, Pamplona y Zaragoza.
At CounselX, we carefully listen to your unique needs and aspirations, showing our dedication to solve your three hard problems: Facilitating Enterprise Client and Law firms: Connecting enterprise clients with specialized legal talent for efficient outsourcing of specific legal tasks. This is me: https://shorturl.at/ctELY Supporting Legal Professionals: Offering a platform for legal experts to find flexible, additional work opportunities that utilize their skills and experience. This is me: https://shorturl.at/eqsAD Empowering Startups: Providing subscription-based legal services to help startups establish strong legal foundations and focus on growth through on-going support. This is me: https://shorturl.at/asKOT
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.